Processing math: 43%
Research article

Mathematical analysis of an age-structured HIV-1 infection model with CTL immune response

  • Received: 14 June 2019 Accepted: 23 August 2019 Published: 28 August 2019
  • In this paper, an age-structured HIV-1 infection model with CTL immune response is investigated. In the model, we consider the infection age (i.e. the time that has elapsed since an HIV virion has penetrated the cell) of infected T cells. The asymptotic smoothness of the semi-flow generated by the system is established. By calculation, the immune-inactivated reproduction rate R0 and the immune-activated reproduction rate R1 are obtained. By analyzing the corresponding characteristic equations, the local stability of an infection-free steady state and a CTL-inactivated infection steady state of the model is established. By using the persistence theory for infinite dimensional system, the uniform persistence of the system is established when R1>1. By means of suitable Lyapunov functionals and LaSalle's invariance principle, it is shown that if R0<1, the infection-free steady state is globally asymptotically stable; if R1<1<R0, sufficient conditions are derived for the global stability of the CTL-inactivated infection steady state; if R1>1, sufficient conditions are obtained for the global attractivity of the CTL-activated infection steady state. Numerical simulations are carried out to illustrate the feasibility of the theoretical results.

    Citation: Xiaohong Tian, Rui Xu, Jiazhe Lin. Mathematical analysis of an age-structured HIV-1 infection model with CTL immune response[J]. Mathematical Biosciences and Engineering, 2019, 16(6): 7850-7882. doi: 10.3934/mbe.2019395

    Related Papers:

    [1] Ting Guo, Zhipeng Qiu . The effects of CTL immune response on HIV infection model with potent therapy, latently infected cells and cell-to-cell viral transmission. Mathematical Biosciences and Engineering, 2019, 16(6): 6822-6841. doi: 10.3934/mbe.2019341
    [2] Cameron Browne . Immune response in virus model structured by cell infection-age. Mathematical Biosciences and Engineering, 2016, 13(5): 887-909. doi: 10.3934/mbe.2016022
    [3] Xuejuan Lu, Lulu Hui, Shengqiang Liu, Jia Li . A mathematical model of HTLV-I infection with two time delays. Mathematical Biosciences and Engineering, 2015, 12(3): 431-449. doi: 10.3934/mbe.2015.12.431
    [4] A. M. Elaiw, A. S. Shflot, A. D. Hobiny . Stability analysis of general delayed HTLV-I dynamics model with mitosis and CTL immunity. Mathematical Biosciences and Engineering, 2022, 19(12): 12693-12729. doi: 10.3934/mbe.2022593
    [5] Ning Bai, Rui Xu . Mathematical analysis of an HIV model with latent reservoir, delayed CTL immune response and immune impairment. Mathematical Biosciences and Engineering, 2021, 18(2): 1689-1707. doi: 10.3934/mbe.2021087
    [6] Abdessamad Tridane, Yang Kuang . Modeling the interaction of cytotoxic T lymphocytes and influenza virus infected epithelial cells. Mathematical Biosciences and Engineering, 2010, 7(1): 171-185. doi: 10.3934/mbe.2010.7.171
    [7] Shingo Iwami, Shinji Nakaoka, Yasuhiro Takeuchi . Mathematical analysis of a HIV model with frequency dependence and viral diversity. Mathematical Biosciences and Engineering, 2008, 5(3): 457-476. doi: 10.3934/mbe.2008.5.457
    [8] Gesham Magombedze, Winston Garira, Eddie Mwenje . Modelling the human immune response mechanisms to mycobacterium tuberculosis infection in the lungs. Mathematical Biosciences and Engineering, 2006, 3(4): 661-682. doi: 10.3934/mbe.2006.3.661
    [9] Jian Ren, Rui Xu, Liangchen Li . Global stability of an HIV infection model with saturated CTL immune response and intracellular delay. Mathematical Biosciences and Engineering, 2021, 18(1): 57-68. doi: 10.3934/mbe.2021003
    [10] Yan Wang, Tingting Zhao, Jun Liu . Viral dynamics of an HIV stochastic model with cell-to-cell infection, CTL immune response and distributed delays. Mathematical Biosciences and Engineering, 2019, 16(6): 7126-7154. doi: 10.3934/mbe.2019358
  • In this paper, an age-structured HIV-1 infection model with CTL immune response is investigated. In the model, we consider the infection age (i.e. the time that has elapsed since an HIV virion has penetrated the cell) of infected T cells. The asymptotic smoothness of the semi-flow generated by the system is established. By calculation, the immune-inactivated reproduction rate R0 and the immune-activated reproduction rate R1 are obtained. By analyzing the corresponding characteristic equations, the local stability of an infection-free steady state and a CTL-inactivated infection steady state of the model is established. By using the persistence theory for infinite dimensional system, the uniform persistence of the system is established when R1>1. By means of suitable Lyapunov functionals and LaSalle's invariance principle, it is shown that if R0<1, the infection-free steady state is globally asymptotically stable; if R1<1<R0, sufficient conditions are derived for the global stability of the CTL-inactivated infection steady state; if R1>1, sufficient conditions are obtained for the global attractivity of the CTL-activated infection steady state. Numerical simulations are carried out to illustrate the feasibility of the theoretical results.


    Human immunodeficiency virus (HIV) is a pathogen that infects T-helper cells of the immune system and can cause Acquired Immune Deficiency Syndrome (AIDS) [1]. These are white blood cells that move around the body, detecting faults and anomalies in cells as well as infections. When HIV targets and infiltrates these cells, it reduces the body's ability to combat other diseases. This increases the risk and impact of opportunistic infections and cancers. In past decades, many works have been developed for HIV-1 infection using simple differential equation models (see, for example, [2,3,4,5,6,7,8]). Let x,y and v denote the concentrations of uninfected target cells (i.e. cells susceptible to HIV-1 infection), productively infected cells, and free virions, respectively. A basic mathematical model describing HIV-1 infection dynamics has been studied in [4,8]:

    ˙x(t)=Λdx(t)βx(t)v(t),˙y(t)=βx(t)v(t)ay(t),˙v(t)=ky(t)uv(t), (1.1)

    where uninfected cells are produced at a rate Λ and die at rate dx per target cell, and become infected at rate βxv, where β is the rate constant describing the infection process; infected cells are produced at rate βxv and die at rate ay; free virions are produced from infected cells at rate ky and are removed at rate uv.

    We note that in system (1.1), the death rate and virus production rate of infected cells are both assumed to be constant. In reality, as argued by Nelson et al. [9], the production of new virus particles(virions) by an infected cell does not occur at a constant rate, but rather ramps up as viral proteins and unspliced viral RNA accumulate within the cytoplasm of an infected cell. In [9], in order to describe this phenomenon, by considering the variations in the death rate of productively infected T cells and the productions rate of viral particles as a function of the length of time a T cells has been infected, Nelson et al. developed and analyzed the following age-structured within-host HIV-1 infection model:

    ˙T(t)=sdT(t)βT(t)V(t),T(a,t)t+T(a,t)a=μ(a)T(a,t),˙V(t)=0p(a)T(a,t)dauV(t), (1.2)

    with boundary condition T(0,t)=βT(t)V(t). In system (1.2), T(a,t) denotes the density of infected T cells of infection age a (i.e. the time that has elapsed since an HIV virion has penetrated the cell) at time t, μ(a) is the age-dependent per capita death rate of infected cells, p(a) is the viral production rate of an infected cell with age a. In [9], Nelson et al. discussed the local stability of the nontrivial equilibrium solution and provided a general stability condition for models with age structure. In [10], by constructing suitable Lyapunov functions, Huang et al. established the global dynamical properties for Nelson's age-structured model without (or with) drug treatment. In [11], Rong et al. considered two models with age-of-infection and combination therapies involving reverse transcriptase, protease, and entry/fusion inhibitors. In [12], considering the infection rate of microparasitic infections is an increasing function of the parasite dose, Xu et al. further investigated a within-host HIV-1 infection model with saturation incidence and age-since-infection structure for infected cells. Recently, great attention has been paid by many researchers to age-structured model of HIV infection due to their greater flexibility in exploring fundamental issues of viral production and death, and allow coupling of biological processes happening on different time scales (see, for example, [10,11,12,13,14,15,16,17]).

    It is worth noting that the effect of immune response is ignored in the models above. However, in most virus infections, cytotoxic T lymphocytes (CTLs) play a critical role in cell-mediated immunity by regulating the functions of other immune cells (such as the B cells and macrophages) and attacking diseased cells and tumors [18]. For HIV-1 infection, the main clinical indicators of that HIV-1 positive patient are in the follow up both the viral load and the CD4+T cells count in blood plasma, therapy is started, make a portion to the immune cells to be toxic thereby introducing toxicity in the immune system of the individual[19]. In [20], Cao et al. have shown that CTL immune response is often associated with better virus control and slower disease progression during the early stage of HIV infection. In [4], in order to discuss the effect of the population dynamics of viral infection with CTL immune response, Nowak et al. proposed the basic HIV-1 infection model with immune response. At present, there are few works on global dynamics in the age-structured within-host HIV-1 infection model with CTL immune response [21,22].

    Motivated by the works of Nelson et al. [9], Nowak et al.[4] and Regoes et al. [23], in the present paper, we are concerned with the effects of age-structured, CTL immune response and saturation incidence on the dynamics of HIV-1 infection. To this end, we consider the following HIV-1 infection model:

    ˙x(t)=Λdx(t)βx(t)v(t)1+αv(t),y(a,t)t+y(a,t)a=μ(a)y(a,t)p(a)y(a,t)z(t), a>0,˙v(t)=0k(a)y(a,t)dauv(t),˙z(t)=z(t)0c(a)y(a,t)dabz(t), (1.3)

    with boundary condition

    y(0,t)=βx(t)v(t)1+αv(t), (1.4)

    and initial condition

    X0:=(x(0),y(,0),v(0),z(0))=(x0,y0(),v0,z0)X, (1.5)

    where X=R+×L1+(0,)×R+×R+, L1+(0,) is the set of all integrable functions from (0,) into R+=[0,). In system (1.3), x(t) represents the concentration of uninfected target T cells at time t, y(a,t) denotes the density of infected T cells of infection age a at time t, v(t) denotes the concentration of infectious free virion at time t, and z(t) denotes the concentration of CTLs at time t. The definitions of all parameters in system (1.3) are listed in Table 1.

    Table 1.  The definitions of the parameters in system (1.1).
    Parameter Description
    Λ The recruitment rate of healthy T cells
    d The per capita death rate of uninfected cells
    u Clearance rate of virions
    α Saturation constant
    β The rate at which an uninfected cell becomes infected by an infectious virus
    a Age of infection, that is, the time since an HIV virion penetrated cell
    b The death rate of CTL cells
    μ(a) The age-dependent per capita death rate of infected cells with age a
    k(a) The viral production rate of infected cells with age a
    p(a) The killing rate of infected cells with age a
    c(a) The proliferate rate of virus-specific CTL cells with age a

     | Show Table
    DownLoad: CSV

    In the sequel, we further make the following assumptions.

    (H1) c,k,p,μL+(0,) with essential upper bounds ˉc,ˉk,ˉp and ˉμ, respectively.

    (H2) There are positive constants μ0,μ1,ˉb and satisfying μ0d, ˉb=bˉcmax{Λμ0,X0X} and μ1=min{μ0,u,ˉb}. μ(a) is a bounded function on R+ satisfying μ(a)μ0 for a0.

    (H3) For any a>0, there exist ak,ac>a such that k(a) is positive in a neighbourhood of ak and c(a) is positive in a neighbourhood of ac.

    Using the theory of age-structured dynamical systems introduced in [24,25], one can show that system (1.3) has a unique solution (x(t),y(,t),v(t),z(t)) satisfying the boundary condition (1.4) and the initial condition (1.5). Moreover, it is easy to show that all solutions of system (1.3) with the boundary condition (1.4) and the initial condition (1.5) are defined on [0,+) and remain positive for all t0. Furthermore, X is positively invariant and system (1.3) exhibits a continuous semi-flow Φ:R+×XX, namely,

    Φt(X0)=Φ(t,X0):=(x(t),y(,t),v(t),z(t)), t0, X0X. (1.6)

    Given a point (x,φ,v,z)X, we have the norm (x,φ,v,z)X:=x+0φ(a)da+v+z.

    The organization of this paper is as follows. In the next section, we establish the asymptotic smoothness of the semi-flow generated by system (1.3). In Section 3, we calculate the immune-inactivated reproduction rate and the immune-activated reproduction rate and discuss the existence of feasible steady states of system (1.3) with the boundary condition (1.4). In Section 4, by analyzing the corresponding characteristic equations, we study the local asymptotic stability of an infection-free steady state and a CTL-inactivated infection steady state of system (1.3), respectively. In Section 5, we show that if the immune-activated reproduction rate is greater than unity, system (1.3) is uniformly persistent. In Section 6, we are concerned with the global stability (attractivity) of each of feasible steady states of system (1.3) by means of Lyapunov functionals and LaSalle's invariance principle. In Section 7, numerical examples are carried out to illustrate the feasibility of theoretical results. A brief conclusion is given in Section 8 to end this work.

    In order to discuss the global dynamics of system (1.3) with the boundary condition (1.4), in this section, we are concerned with the boundedness of solutions of system (1.3) and the asymptotic smoothness of the semi-flow {Φ(t)}t0 generated by system (1.3).

    In this subsection, we prove the boundedness of semi-flow {Φ(t)}t0. Denote

    X0X=x0+0y0(a)da+v0+z0

    and

    N(t)=Φ(t,X0)X=x(t)+0y(a,t)da+v(t)+z(t).

    Proposition 2.1. Let Φt be defined as in (1.6). Then the following statements hold.

    (ⅰ) ddtΦt(X0)XΛ+ˉkmax{Λμ0,X0X}μ1N(t) for all t0;

    (ⅱ) Φt(X0)Xmax{1μ1[Λ+ˉkmax{Λμ0,X0X}],X0X} for all t0;

    (ⅲ) lim supt+Φt(X0)X1μ1[Λ+ˉkmax{Λμ0,X0X}];

    (ⅳ) Φt is point dissipative: there is a bounded set that attracts all points in X.

    Proof.. Let Φt(X0)=Φ(t,X0):=(x(t),y(,t),v(t),z(t)) be any nonnegative solution of system (1.3) with the boundary condition (1.4) and the initial condition (1.5). We derive from system (1.3) that

    ddt(x(t)+0y(a,t)da)=Λdx(t)βx(t)v(t)1+αv(t)y(a,t)|00(μ(a)+p(a)z(t)y(a,t)daΛμ0(x(t)+0y(a,t)da). (2.1)

    The variation of constants formula implies

    x(t)+0y(a,t)daΛμ0eμ0t(Λμ0X0X),

    which yields

    x(t)+0y(a,t)damax{Λμ0,X0X} (2.2)

    for all t0. We derive from Eq (2.2) and the third and fourth equations of system (1.3) that

    dv(t)dtˉkmax{Λμ0,X0X}uv(t),dz(t)dtˉcmax{Λμ0,X0X}z(t)bz(t). (2.3)

    It follows from Eqs (2.1) and (2.3) that

    ddtN(t)Λμ0(x(t)+0y(a,t)da)+ˉkmax{Λμ0,X0X}uv(t)ˉbz(t)Λ+ˉkmax{Λμ0,X0X}μ1N(t). (2.4)

    Again, using variation of constants formula we have from Eq (2.4) that

    N(t)max{1μ1[Λ+ˉkmax{Λμ0,X0X}],X0X}

    for all t0. This completes the proof.

    The following results are direct consequences of Proposition 2.1.

    Proposition 2.2. If X0X and X0XK for some K1μ1[Λ+ˉkmax{Λμ0,X0X}], then

    x(t)K, 0y(a,t)daK, v(t)K, z(t)K (2.5)

    for all t0.

    Proposition 2.3. Let CX be bounded. Then

    (1) Φt(C) is bounded;

    (2) Φt is eventually bounded on C.

    In this subsection, we show the asymptotic smoothness of the semi-flow {Φ(t)}t0.

    Denote

    π(a)=ea0(μ(s)+p(s)z)ds,aR+. (2.6)

    It follows from (H1) and (H2) that 0<e(ˉμ+ˉpK)aπ(a)eμ0a for all a0. Clearly, π(a) is a deceasing function.

    Let (x(t),y(,t),v(t),z(t)) be a solution of system (1.3) with the boundary condition (1.4) and the initial condition (1.5). Integrating the second equation of system (1.3) along the characteristic line ta=const., we have

    y(a,t)={L(ta)π(a), 0a<t,y0(at)π(a)π(at), 0ta, (2.7)

    where L(t):=y(0,t)=βx(t)v(t)1+αv(t).

    Using a similar argument as that in [12], it's easy to verify the following result.

    Proposition 2.4. The function L(t) is Lipschitz continuous on R+.

    Before giving our main results, we need the following Lemmas.

    Lemma 2.1. [26] The semi-flow Φ:R+×X+X+ is asymptotically smooth if there are maps Θ,Ψ:R+×X+X+ such that Φ(t,x)=Θ(t,x)+Ψ(t,x) and the following hold for any bounded closed set CX+ that is forward invariant under Φ:

    (1) limt+diamΘ(t,C)=0;

    (2) there exists tC0 such that Ψ(t,C) has compact closure for each ttC.

    Lemma 2.2. [26] Let C be a subset of L1(R+). Then C has compact closure if and only if the following assumptions hold:

    (ⅰ) supfC0|f(a)|da<;

    (ⅱ) limrr|f(a)|da=0 uniformly in fC;

    (ⅲ) limh0+0|f(a+h)f(a)|da=0 uniformly in fC;

    (ⅳ) limh0+h0|f(a)|da=0 uniformly in fC.

    By applying Lemmas 2.1 and 2.2, we now prove the asymptotic smoothness of the semiflow Φ generated by system (1.3).

    Theorem 2.1. The semi-flow Φ generated by system (1.3) is asymptotically smooth.

    Proof. We first decompose the semi-flow Φ into two parts: for t0, let Ψ(t,X0):=(x(t),˜y(,t),v(t),z(t)),Θ(t,X0):=(0,˜ϕy(,t),0,0), where

    ˜y(a,t)={L(ta)π(a), 0at,0, 0t<a,˜ϕy(a,t)={0, 0at,y0(at)π(a)π(at), 0t<a. (2.8)

    Clearly, we have Φ=Θ+Ψ for t0.

    Let C be a bounded subset of X and K>[Λ+ˉkmax{Λμ0,X0X}]/μ1 the bound for C. Let Φ(t,X0)=(x(t),y(,t),v(t),z(t)), where X0=(x0,y0(),v0,z0)C. Then

    Θ(t,X0)=˜ϕy(,t)L1=0|˜ϕy(a,t)|da=ty0(at)π(a)π(at)da. (2.9)

    Letting at=σ, it follows from (2.9) that

    ˜ϕy(,t)L1=0y0(σ)eσ+tσ(μ(s)+p(s)z)dsdσKeμ0t, (2.10)

    yielding limt+Θ(t,X0)=0, hence, limt+diam Θ(t,C)=0 and the assumption (1) in Lemma 2.1 holds.

    In the following we show that Ψ(t,C) has compact closure for each ttC by verifying the assumptions (ⅰ)–(ⅳ) of Lemma 2.2. From Proposition 2.2 we see that x(t),v(t) and z(t) remain in the compact set [0,K]. Next, we show that ˜y(a,t) remain in a pre-compact subset of L1+ independent of X0. It is easy to show that ˜y(a,t)ˉLeμ0a, where ˉL=βK2/(1+αK). Therefore, the assumptions (ⅰ), (ⅱ) and (ⅳ) of Lemma 2.2 follow directly. We need only to verify that (ⅲ) of Lemma 2.2 holds. Since we are concerned with the limit as h0, we assume that h(0,t). In this case, we have

    0|˜y(a+h,t)˜y(a,t)|da=th0|L(tah)π(a+h)L(ta)π(a)|da+tthL(ta)π(a)dath0L(tah)|π(a+h)π(a)|da+th0|L(ath)L(at)|π(a)da+tthL(ta)π(a)da. (2.11)

    By Proposition 2.2., there is positive constant ML such that

    |L(a+h)L(a)|MLh. (2.12)

    It follows from (2.11) and (2.12) that

    0|˜y(a+h,t)˜y(a,t)|daˉLth0π(a)a+ha(μ(s)+p(s)z)dsda+MLh+ˉLh[(ˉμ+ˉpK)ˉL+ML+ˉL]h. (2.13)

    Hence, the condition (ⅲ) of Lemma 2.2 holds. By Lemma 2.1, the asymptotic smoothness of the semi-flow Φ generated by system (1.3) follows. This completes the proof.

    The following result is immediate from Theorem 2.33 in [26] and Theorem 2.1.

    Theorem 2.2. There exists a global attractor A of bounded sets in X.

    In this section, we are concerned with the local stability of each of feasible steady states of system (1.3) with the boundary condition (1.4).

    Clearly, system (1.3) always has an infection-free steady state E0(Λ/d,0,0,0). If system (1.3) has a CTL-inactivated infection steady state E1(x1,y1(a),v1,0), then it must satisfy the following equations:

    Λdx1βx1v11+αv1=0,dday1(a)=μ(a)y1(a),0k(a)y1(a)da=uv1,y1(0)=βx1v11+αv1. (3.1)

    We derive from the first equation of (3.1) that

    x1=Λ(1+αv1)d+(αd+β)v1. (3.2)

    It follows from the second equation of (3.1) that

    y1(a)=y1(0)ϕ1(a), (3.3)

    where ϕ1(a)=ea0μ(s)ds. We obtain from the third equation of (3.1) and (3.3) that

    v1=y1(0)0k(a)ϕ1(a)dau. (3.4)

    On substituting (3.2)–(3.4) into the fourth equation of (3.1), we have

    y1(0)=du(αd+β)0k(a)ϕ1(a)da(R01), (3.5)

    where

    R0=Λβ0k(a)ϕ1(a)dadu. (3.6)

    Here, R0 is called the immune-inactivated reproduction rate of system (1.3), which represents the number of newly infected cells produced by one infected cell during its lifespan. Hence, if R0>1, in addition to the infection-free steady state E0, system (1.3) admits a CTL-inactivated infection steady state E1(x1,y1(a),v1,0), where

    x1=Λ(1+αv1)d+(αd+β)v1,y1(a)=duϕ1(a)(αd+β)0k(a)ϕ1(a)da(R01),v1=dαd+β(R01).

    Further, if system (1.3) has a CTL-activated infection steady state E(x,y(a),v,z), then it must satisfy the following equations:

    Λdxβxv1+αv=0,dday(a)=μ(a)y(a)p(a)y(a)z,0k(a)y(a)da=uv,z(0c(a)y(a)dab)=0,y(0)=βxv1+αv. (3.7)

    It follows from the first equation of (3.7) that

    x=Λ(1+αv)d+(αd+β)v. (3.8)

    We obtain from the second equation of (3.7) that

    y(a)=y(0)ϕ1(a)ϕ2(a,z), (3.9)

    where ϕ2(a,z)=ea0p(s)zds. When z0, it follows from (3.9) and the fourth equation of (3.7) that

    y(0)=b0c(a)ϕ1(a)ϕ2(a,z)da. (3.10)

    We derive from the third equation of (3.7) and (3.10) that

    v=b0k(a)ϕ1(a)ϕ2(a,z)dau0c(a)ϕ1(a)ϕ2(a,z)da. (3.11)

    On substituting (3.8), (3.10) and (3.11) into the first equation of (3.7), we have that

    ΛβG1(z)G2(z)=duG2(z)+b(αd+β)G1(z), (3.12)

    where

    G1(z)=0k(a)ϕ1(a)ϕ2(a,z)da,G2(z)=0c(a)ϕ1(a)ϕ2(a,z)da. (3.13)

    From (3.13), it is easy to show that

    0<Gi(z)Gi(0)andGi(z)0,i=1,2. (3.14)

    Denote

    Φ(z)=ΛβG1(z)G2(z)duG2(z)b(αd+β)G1(z)=[duG2(z)+b(αd+β)G1(z)](ΛβG1(z)G2(z)duG2(z)+b(αd+β)G1(z)1). (3.15)

    Clearly

    Φ(0)=[duG2(0)+b(αd+β)G1(0)](R11), (3.16)

    where

    R1=Λβ0k(a)ϕ1(a)da0c(a)ϕ1(a)dadu0c(a)ϕ1(a)da+b(αd+β)0k(a)ϕ1(a)da.

    Here, R1 is called the immune-activated reproduction rate which expresses the CTL load during the lifespan of a CTL cell. Clearly, if R1>1, it therefore follows from (3.14) and (3.16) that Φ(0)>0. Further, for z>0 sufficiently large, we note that

    ΛβG1(z)G2(z)duG2(z)+b(αd+β)G1(z)0,

    Then by (3.15), for z>0 sufficiently large, there exists a z0>0 such that Φ(z0)<0. Therefore, if R1>1, there exists a z(0,z0) such that Φ(z)=0. Hence, if R1>1, in addition to the infection-free steady state E0 and the CTL-inactivated infection steady state E1, system (1.3) exists a unique infection steady state E(x,y(a),v,z).

    In this section, we are concerned with the local stability of the infection-free steady state E0 and the CTL-inactivated infection steady state E1 of system (1.3), respectively.

    We first consider the local stability of the infection-free steady state E0(Λ/d,0,0,0).

    Let x(t)=x0(t)+Λ/d,y(a,t)=y0(a,t),v(t)=v0(t),z(t)=z0(t). Linearizing system (1.3) at the steady state E0, it follows that

    ˙x0(t)=dx0(t)Λβdv0(t),y0(a,t)t+y0(a,t)a=μ(a)y0(a,t),˙v0(t)=0k(a)y0(a,t)dauv0(t),˙z0(t)=bz0(t),y0(0,t)=Λβdv0(t). (4.1)

    Looking for solutions of system (4.1) of the form x0(t)=x01eλt,y0(a,t)=y01(a)eλt,v0(t)=v01eλt, z0(t)=z01eλt, where x01,y01(a),v01 and z01 will be determined later, one obtains the characteristic equation of system (1.3) at the steady state E0 of the form:

    (λ+b)(1f1(λ))=0, (4.2)

    where

    f1(λ)=Λβd(λ+u)0k(a)e(λ+μ(s))dsda.

    Clearly, Eq (4.2) always has one negative real root λ=b, other roots of (4.2) are determined by equation

    f1(λ)=1. (4.3)

    Clearly, we have f1(0)=R0. It is easy to show that f1(λ)<0 and limλ+f1(λ)=0. Hence, f1(λ) is a decreasing function. Therefore, if R0>1, then f1(λ)=1 has a unique positive root. Hence, if R0>1, the steady state E0 is unstable.

    Now, we claim that all roots of Eq (4.3) have negative real parts if R0<1. If not, there exists a root λ1=a1+ib1 with a10. In this case, substituting λ1 into (4.3), we obtain

    |f1(λ1)|Λβ0k(a)ϕ1(a)dadu=R0<1,

    a contradiction. Hence, if R0<1, all roots of equation (4.2) have negative real parts. Accordingly, the steady state E0(Λ/d,0,0,0) is locally asymptotically stable if R0<1.

    Now, we consider the local stability of the CTL-inactivated infection steady state E1(x1, y1(a),v1,0).

    Let x(t)=x1(t)+x1,y(a,t)=y1(a,t)+y1(a),v(t)=v1(t)+v1,z(t)=z1(t). Linearizing system (1.3) at the steady state E1, we obtain that

    ˙x1(t)=(d+βv11+αv1)x1(t)βx1(1+αv1)2v1(t),y1(a,t)t+y1(a,t)a=μ(a)y1(a,t)p(a)y1(a)z1(t),˙v1(t)=0k(a)y1(a,t)dauv1(t),˙z1(t)=(0c(a)y1(a)dab)z1(t),y1(0,t)=βv11+αv1x1(t)+βx1(1+αv1)2v1(t). (4.4)

    Looking for solutions of system (4.4) of the form x1(t)=x11eλt,y1(a,t)=y11(a)eλt,v1(t)=v11eλt, z1(t)=z11eλt, where x11,y11(a),v11 and z11 will be determined later, we obtain the following linear eigenvalue problem:

    (λ+d+βv11+αv1)x11=βx1(1+αv1)2v11,y11(a)=(λ+μ(a))y11(a)p(a)y1(a)z11,(λ+u)v11=0k(a)y11(a)da,λ=0c(a)y1(a)dab,y11(0)=βv11+αv1x11+βx1(1+αv1)2v11. (4.5)

    We derive from the fourth equation of (4.5) that

    λ=(du0c(a)ϕ1(a)da(αd+β)0k(a)ϕ1(a)da+b)(R11). (4.6)

    Clearly, If R1>1, λ>0, in this case, E1 is unstable. If R1<1<R0, it follows from the fourth equation of (4.4) that z10, hence, in the following discussion, we only consider the simplified system

    (λ+d+βv11+αv1)x11=βx1(1+αv1)2v11,y11(a)=(λ+μ(a))y11(a),(λ+u)v11=0k(a)y11(a)da,y11(0)=βv11+αv1x11+βx1(1+αv1)2v11. (4.7)

    It follows from the first and the second equations of system (4.7) that

    x11=βx1(1+αv1)[(λ+d)(1+αv1)+βv1]v11, (4.8)

    and

    y11(a)=y11(0)ea0(λ+μ(s))ds. (4.9)

    We derive from the third equation of system (4.5) that

    v11=y11(0)0k(a)ea0(λ+μ(s))dsdaλ+u. (4.10)

    On substituting (4.8)–(4.10) into the fifth equation of system (4.7), one obtains that

    f2(λ)=1, (4.11)

    where

    f2(λ)=βx1(1+αv1)2(λ+d)0k(a)ea0(λ+μ(s))dsda(λ+u)(λ+d+βv11+αv1).

    We claim that all roots of Eq (4.11) have negative real parts. Otherwise, Eq (4.11) has at least one root λ2=a2+ib2 satisfying a20. In this case, we have

    |f2(λ2)|11+αd(αd+β)(R01)u|a2+u+ib2|. (4.12)

    Clearly, if R0>1, then 1+αd(αd+β)(R01)>1, which mean that |f2(λ2)|<1, a contradiction. Therefore, if R1<1<R0, the CTL-inactivated infection steady state E1 is locally asymptotically stable.

    In conclusion, we have the following result.

    Theorem 4.1. For system (1.3) with the boundary condition (1.4), if R0<1, the infection-free steady state E0(Λ/d,0,0,0) is locally asymptotically stable; if R1<1<R0, E0 is unstable and the CTL-inactivated infection steady state E1(x1,y1(a),v1,0) exists and is locally asymptotically stable.

    In this section, we investivate the uniform persistence of the semi-flow {Φ(t)}t0 generated by system (1.3) when the immune-activated reproduction rate R1>1.

    Define

    ˉa1=inf{a:ak(u)du=0},ˉa2=inf{a:ac(u)du=0}.

    Noting that k(),c()L+(0,), we have ˉa1>0,ˉa2>0.

    Denote

    X=L1+(0,+)×R+×R+,ˉa=max{ˉa1.ˉa2}˜Y={(y(,t),v(t),z(t))X:ˉa0y(a,t)da+v(t)+z(t)>0},

    and

    Y=R+טY,Y=XY,˜Y=X˜Y.

    By [36] and using a similar argument as in the proof of Theorem 5.1 in [38], we have the following result.

    Proposition 5.1. The subsets Y and Y are both positively invariant under the semi-flow {Φ(t)}t0, namely, Φ(t,Y)Y and Φ(t,Y)Y for t0.

    The following result is helpful to the proof of uniform persistence of the semi-flow {Φ(t)}t0 generated by system (1.3).

    Theorem 5.1. The infection-free steady state E0(A/μ,0,0,0) is globally asymptotically stable for the semi-flow {Φ(t)}t0 restricted to Y.

    Proof. Let (x0,y0(),v0,z0)Y. Then (y0(),v0,z0)˜Y. We consider the following system

    y(a,t)t+y(a,t)a=μ(a)y(a,t)p(a)y(a,t)z(t),˙v(t)=0k(a)y(a,t)dauv(t),˙z(t)=z(t)0c(a)y(a,t)dabz(t),y(0,t)=βx(t)v(t)1+αv(t),y(a,0)=y0(a), v(0)=0, z(0)=0. (5.1)

    Since lim supt+x(t)Λ/d, by comparison principle, we have

    y(a,t)ˆy(a,t),v(t)ˆv(t),z(t)ˆz(t), (5.2)

    where ˆy(a,t),ˆv(t) and ˆz(t) satisfy the following auxiliary system

    ˆy(a,t)t+ˆy(a,t)a=μ(a)ˆy(a,t)p(a)ˆy(a,t)z(t),˙ˆv(t)=0k(a)ˆy(a,t)dauˆv(t),˙ˆz(t)=ˆz(t)0c(a)ˆy(a,t)dabˆz(t),ˆy(0,t)=Λβdˆv(t)1+αˆv(t),ˆy(a,0)=y0(a), ˆv(0)=0, ˆz(0)=0. (5.3)

    Solving the first equation of system (5.3), we have

    ˆy(a,t)={ˆL(ta)π(a), 0a<t,y0(at)π(a)π(at),0ta, (5.4)

    where

    ˆL(t):=ˆy(0,t)=Λβdˆv(t)1+αˆv(t). (5.5)

    On substituting (5.5) into the second and the third equations of (5.3), it follows that

    ˙ˆv(t)=t0k(a)ˆL(ta)π(a)dauˆv(t)+L1(t),˙ˆz(t)=ˆz(t)t0c(a)ˆL(ta)π(a)dabˆz(t)+ˆz(t)L2(t),ˆv(0)=0,ˆz(0)=0. (5.6)

    where

    L1(t)=tk(a)y0(at)π(a)π(at)da,L2(t)=tc(a)y0(at)π(a)π(at)da,

    Since (y0(),v0,z0)˜Y, we have Li(t)0(i=1,2) for all t0. It therefore follows from (5.6) that

    ˙ˆv(t)=t0k(a)ˆL(ta)π(a)dauˆv(t),˙ˆz(t)=ˆz(t)t0c(a)ˆL(ta)π(a)dabˆz(t),ˆL(t):=ˆy(0,t)=Λβdˆv(t)1+αˆv(t),ˆv(0)=0,ˆz(0)=0. (5.7)

    It is easy to show that system (5.7) has a unique solution ˆv(t)=0,ˆz(t)=0,ˆL(t)=0.

    We obtain from (5.4) that ˆy(a,t)=0 for 0a<t. For at, we have

    ˆy(a,t)L1=y0(at)π(a)π(at)L1eμ0ty0L1,

    which yields limt+ˆy(a,t)=0. By comparison principle, it follows that limt+y(a,t)=0 and v(t)=0,z(t)=0 as t tends to infinity. We obtain from the first equation of system (1.3) that limt+x(t)=Λ/d. This completes the proof.

    Using a similar argument as that in the proof of Theorem 5.1, we have the following result.

    Theorem 5.2. The CTL-inactivated infection steady state E1(x1,y1(a),v1,0) is globally asymptotically stable for the semi-flow {Φ(t)}t0 restricted to Y.

    Theorem 5.3. If R1>1, then the semi-flow {Φ(t)}t0 generated by system (1.3) is uniformly persistent with respect to the pair (Y,Y); that is, there exists an ε>0 such that lim inft+Φ(t,x)Xε for xY. Furthermore, there is a compact subset A0Y which is a global attractor for {Φ(t)}t0 in Y.

    Proof. By Theorems 5.1 and 5.2, we see that the infection-free steady state E0(A/μ,0,0,0) and the CTL-inactivated infection steady state E1(x1,y1(a),v1,0) are globally asymptotically stable in Y. Hence, applying Theorem 4.2 in [35], in the following, we verify that

    Ws(Ei)Y=(i=0,1),

    where

    Ws(E0)={xY:limt+Φ(t,x)=E0},Ws(E1)={xY:limt+Φ(t,x)=E1}.

    Here, we only show W^s(E_1)\cap \mathcal {Y} = \emptyset holds since the proof of W^s(E_0)\cap \mathcal {Y} = \emptyset is simple. Assume W^s(E_1)\cap \mathcal {Y}\neq \emptyset . Then there exists a solution w\in \mathcal {Y} such that \Phi(t, w) \rightarrow E_1 as t \rightarrow \infty . In this case, one can find a sequence \{w_n\}\subset \mathcal {Y} such that

    \|\Phi(t, w_n)-\bar{w}\|_{\mathscr{X}} \lt \frac{1}{n}, \ t\geq 0,

    where \bar{w} = (x_1, y_1(a), v_1, 0) .

    Denote \Phi(t, w_n) = (x_n(t), y_n(\cdot, t), v_n(t), z_n(t)) and w_n = (x_n(0), y_n(\cdot, 0), v_n(0), z_n(0)) . Since \mathscr{R}_1 > 1 , we can choose n sufficiently large satisfying x_1-\frac{1}{n} > 0 and

    \begin{equation} \begin{aligned} \left( \frac{du\int_{0}^{\infty}c(a)\phi_{1}(a){\rm d}a}{( \alpha d+ \beta)\int_{0}^{\infty}k(a)\phi_{1}(a){\rm d}a}+b\right) (\mathscr{R}_1-1) \gt \frac{1}{n}\int_{0}^{\infty}c(a){\rm d}a \end{aligned} \end{equation} (5.8)

    For such an n > 0 , there exists a T_1 > 0 such that for t > T_1 ,

    \begin{equation} \begin{aligned} &x_1- \frac{1}{n} \lt x_n(t) \lt x_1+ \frac{1}{n}, \quad y_1(a)- \frac{1}{n}\leq y_n(\cdot, t)\leq y_1(a)+ \frac{1}{n}, \\ &v_1- \frac{1}{n}\leq v_n(t)\leq v_1+ \frac{1}{n}, \quad 0\leq z_n(t)\leq \frac{1}{n}. \end{aligned} \end{equation} (5.9)

    Consider the following auxiliary system

    \begin{equation} \begin{aligned} & \frac{ \partial \tilde{y}(a, t)}{ \partial t}+ \frac{ \partial \tilde{y}(a, t)}{ \partial a} = -\mu(a)\tilde{y}(a, t)-p(a)\tilde{y}(a, t) \frac{1}{n}, \\ & \dot {\tilde{v}}(t) = \int_{0}^{\infty}k(a)\tilde{y}(a, t){\rm d}a-u \tilde{v}(t), \\ & \dot {\tilde{z}}(t) = {\tilde{z}}(t)\left(\int_{0}^{\infty}c(a)\left(y_1(a)- \frac{1}{n}\right){\rm d}a-b\right), \\ & \tilde{y}(0, t) = \frac{ \beta \left(x_1-\frac{1}{n}\right) \tilde{v}(t)}{1+\frac{ \alpha}{n}}. \end{aligned} \end{equation} (5.10)

    It is easy to show that if \mathscr{R}_1 > 1 , system (5.10) has a unique steady state E_0(0, 0, 0) .

    Looking for solutions of system (5.10) of the form \tilde{y}(a, t) = \tilde{y}_1(a)e^{ \lambda t}, \tilde{v}(t) = \tilde{v}_1 e^{ \lambda t}, \tilde{z}(t) = \tilde{z}_1 e^{ \lambda t}, where the function \tilde{y}_1(a) and the constants \tilde{v}_1, \tilde{z}_1 will be determined later, we obtain the following linear eigenvalue problem:

    \begin{equation} \begin{aligned} &\tilde{y}_1^{ \prime}(a) = -( \lambda+\mu(a))\tilde{y}_1(a)-p(a)\tilde{y}_1(a) \frac{1}{n}, \\ &\int_{0}^{\infty}k(a)\tilde{y}_1(a){\rm d}a = ( \lambda+\mu)\tilde{v}_1, \\ & \lambda = \int_{0}^{\infty}c(a)\left(y_1(a)- \frac{1}{n}\right){\rm d}a-b, \\ &\tilde{y}_1(0) = \frac{ \beta \left(x_0-\frac{1}{n}\right) \tilde{v}_1}{1+\frac{ \alpha}{n}}. \end{aligned} \end{equation} (5.11)

    We derive from the third equation of (5.11) that

    \begin{equation} \lambda = \left( \frac{du\int_{0}^{\infty}c(a)\phi_{1}(a){\rm d}a}{( \alpha d+ \beta)\int_{0}^{\infty}k(a)\phi_{1}(a){\rm d}a}+b\right) (\mathscr{R}_1-1)- \frac{1}{n}\int_{0}^{\infty}c(a){\rm d}a. \end{equation} (5.12)

    Clearly, if \mathscr{R}_1 > 1 , Eq (5.11) has at least one positive root \lambda_0 , which yields the solution (\tilde{y}(\cdot, t), \tilde{v}(t), \tilde{z}(t)) of system (5.10) is unbounded. By comparison principle, the solution \Phi(t, y_n) of system (1.3) is unbounded, which contradicts Proposition 5.1. Therefore, the semi-flow \{\Phi(t)\}_{t\geq 0} generated by system (1.3) is uniformly persistent. Furthermore, there is a compact subset \mathcal {A}_0\subset \mathcal {Y} which is a global attractor for \{\Phi(t)\}_{t\geq 0} in \mathcal {Y} . This completes the proof.

    In this section, we discuss the global stability of each of feasible steady states of system (1.3). The strategy of proofs is to use suitable Lyapunov functionals and LaSalles invariance principle. Further, we employ a Volterra type functional defined by G(x) = x-1-\ln x in [37], which is positive and attains minimum value 0 at x = 1 .

    We first give a result on the global stability of the infection-free steady state E_0(\Lambda/d, 0, 0, 0) of system (1.3).

    Theorem 6.1. If \mathscr{R}_0 < 1 , the infection-free steady state E_0(\Lambda/d, 0, 0, 0) of system (1.3) is globally asymptotically stable.

    Proof. Let (x(t), y(a, t), v(t), z(t)) be any positive solution of system (1.3) with the boundary condition (1.4). Denote x_0 = \Lambda/d.

    Define

    \begin{equation} \begin{aligned} V_1(t) = &x(t)-x_0-x_0\ln \frac{x(t)}{x_0}+\int_{0}^{\infty}F_1(a)y(a, t){\rm d}a+k_{1}v(t), \end{aligned} \end{equation} (6.1)

    where the positive constant k_{1} and the nonnegative kernel function F_1(a) will be determined later.

    Calculating the derivative of V_1(t) along positive solutions of system (1.3), it follows that

    \begin{equation} \begin{aligned} \frac{{\rm d}}{{\rm d}t}V_1(t) = &\left(1- \frac{x_0}{x(t)}\right)\left[\Lambda-d x(t)- \frac{ \beta x(t)v(t)}{1+ \alpha v(t)}\right]\\ & +\int_{0}^{\infty}F_1(a) \frac{ \partial y(a, t)}{ \partial t}{\rm d}a +k_{1}\left[\int_{0}^{\infty}k(a)y(a, t){\rm d}a-u v(t)\right]. \end{aligned} \end{equation} (6.2)

    On substituting \Lambda = d x_0 , \frac{ \partial y(a, t)}{ \partial t} = -(\mu(a)+p(a)z(t))y(a, t)-\frac{ \partial y(a, t)}{ \partial a} into Eq (6.2), one obtains

    \begin{equation} \begin{aligned} \frac{{\rm d}}{{\rm d}t}V_1(t) = &\left(1- \frac{x_0}{x(t)}\right)\left[-d (x(t)-x_0)\right]\\ &- \frac{ \beta x(t)v(t)}{1+ \alpha v(t)}+ \frac{ \beta x_0 v(t)}{1+ \alpha v(t)}-\int_{0}^{\infty}F_1(a) \frac{ \partial y(a, t)}{ \partial a}{\rm d}a\\ &-\int_{0}^{\infty}F_1(a)\mu(a)y(a, t){\rm d}a+k_{1}\int_{0}^{\infty}k(a)y(a, t){\rm d}a-k_{1}uv(t)\\ = &\left(1- \frac{x_0}{x(t)}\right)\left[-d (x(t)-x_0)\right]\\ &- \frac{ \beta x(t)v(t)}{1+ \alpha v(t)}+ \frac{ \beta x_0 v(t)}{1+ \alpha v(t)}-F_1(a)y(a, t)|_0^\infty+\int_{0}^{\infty}F_1'(a)y(a, t){\rm d}a\\ &-\int_{0}^{\infty}F_1(a)\mu(a)y(a, t){\rm d}a +k_{1}\int_{0}^{\infty}k(a)y(a, t){\rm d}a-k_{1} uv(t).\\ \end{aligned} \end{equation} (6.3)

    Choose

    k_{1} = \frac{ \beta x_0}{u}, \quad F_1(a) = k_{1}\int_{a}^{\infty}k(u)e^{-\int_{a}^{u}\mu(s){\rm d}s}{\rm d}u,

    Then, we have

    \begin{equation} \begin{aligned} F_1(0) = & \frac{ \beta x_0}{u}\int_{0}^{\infty}k(a)e^{-\int_{0}^{a}\mu(s){\rm d}s}{\rm d}a = \mathscr{R}_0, \\ F_1'(a) = &- \frac{ \beta x_0}{u}k(a)+\mu(a)F_1(a), \quad \lim\limits_{a \rightarrow+\infty}f_1(a) = 0. \end{aligned} \end{equation} (6.4)

    We therefore obtain from (6.3)–(6.4) that

    \begin{equation} \begin{aligned} \frac{{\rm d}}{{\rm d}t}V_1(t) = &\left(1- \frac{x_0}{x(t)}\right)\left[-d (x(t)-x_0)\right]+(\mathscr{R}_0-1) \frac{ \beta x(t)v(t)}{1+ \alpha v(t)}- \frac{ \alpha \beta x_0 v(t)^2}{1+ \alpha v(t)}\\ &-z(t)\int_{0}^{\infty}F_1(a)p(a)y(a, t){\rm d}a. \end{aligned} \end{equation} (6.5)

    Clearly, if \mathscr{R}_0 < 1 , we obtain from (6.5) that V_1^{ \prime}(t)\leq 0 and V_1^{ \prime}(t) = 0 implies that x = x_0, y(a, t) = 0 and v = 0 . Hence, the largest invariant subset of \{V_1^{ \prime}(t) = 0\} is the singleton (x_0, 0, 0) . Further, for \varepsilon > 0 sufficiently small satisfying \int_{0}^{\infty}c(a)\varepsilon {\rm d}a-b < 0 , there is a T > 0 , such that if t > T , y(a, t) < \varepsilon . It therefore follows from the fourth equation of system (1.3) that for t > T ,

    \dot{z}(t)\leq \left(\int_{0}^{\infty}c(a)\varepsilon {\rm d}a-b\right)z(t).

    By comparison, we derive that

    \lim\limits_{t\rightarrow +\infty}z(t) = 0.

    From Section 4, we see that if \mathscr{R}_0 < 1 , E_0 is locally asymptotically stable. Accordingly, the global asymptotic stability of E_0 of system (1.3) follows from LaSalle's invariance principle. This completes the proof.

    In the following, we establish the global asymptotic stability of the CTL-inactivated infection steady state E_1(x_1, y_1(a), v_1, 0) and the global attractivity of the CTL-activated infection steady state E^*(x^*, y^*(a), v^*, z^*) of system (1.3), respectively.

    Denote

    D_0 = \left\{(x^0, y_0, v^0, z^0)\in \mathscr{X}\mid \int_0^\infty k(a)y_0(a) {\rm d}a \gt 0, \int_0^\infty c(a)y_0(a) {\rm d}a \gt 0\right\}.

    In order to guarantee the Lyapunov functional in proving the global stability of E_1 and E^* is well-defined in infinite dimension, we make the following assumption:

    (H4) x^0 > 0, v^0 > 0, z^0 > 0, \int_0^\infty \mid \ln y_0(a)\mid {\rm d}a < +\infty.

    We now define a positive function

    \begin{equation} \begin{aligned} F_2(a) = \frac{ \beta x_1}{u(1+ \alpha v_1)}\int_{a}^{\infty}k(u)e^{-\int_{a}^{u}\mu(s){\rm d}s}{\rm d}u. \end{aligned} \end{equation} (6.6)

    Then, we have

    \begin{equation} \begin{aligned} F_2(0) = \frac{ \beta x_1}{u(1+ \alpha v_1)}\int_{0}^{\infty}k(a)e^{-\int_{0}^{a}\mu(s){\rm d}s}{\rm d}a = 1, \end{aligned} \end{equation} (6.7)

    and

    \begin{equation} \begin{aligned} \lim\limits_{a \rightarrow\infty}F_2(a) = 0, \quad F_2'(a) = - \frac{ \beta x_1}{u(1+ \alpha v_1)}k(a)+\mu(a)F_2(a). \end{aligned} \end{equation} (6.8)

    Theorem 6.2. Assume there exists a positive constant k_{2} satisfying F_2(a)p(a) = k_{2}c(a) . If (H4) holds, then the CTL-inactivated infection steady state E_1(x_1, y_1(a), v_1, 0) of system (1.3) is globally asymptotically stable if \mathscr{R}_1 < 1 < \mathscr{R}_0 .

    Proof. Let (x(t), y(a, t), v(t), z(t)) be any positive solution of system (1.3) with the boundary condition (1.4).

    Define

    \begin{equation} \begin{aligned} V_2(t) = &x_1G\left( \frac{x(t)}{x_1}\right)+\int_{0}^{\infty}F_2(a)y_1(a)G\left( \frac{y(a, t)}{y_1(a)}\right){\rm d}a + \frac{ \beta x_1}{u(1+ \alpha v_1)}v_1G\left( \frac{v(t)}{v_1}\right)+k_{2} z(t). \end{aligned} \end{equation} (6.9)

    Using a similar argument as that in the proof of Lemmas 7.1 and 7.2 in [27], one can show that all integrals involved in V_2(t) are finite.

    Calculating the derivative of V_2(t) along positive solutions of system (1.3), it follows that

    \begin{equation} \begin{aligned} \frac{{\rm d}}{{\rm d}t}V_2(t) = &\left(1- \frac{x_1}{x(t)}\right)\left[\Lambda-d x(t)- \frac{ \beta x(t)v(t)}{1+ \alpha v(t)}\right]\\ & +\int_{0}^{\infty}F_2(a)y_1(a) \frac{ \partial}{ \partial t} G\left( \frac{y(a, t)}{y_1(a)}\right){\rm d}a\\ & + \frac{ \beta x_1}{u(1+ \alpha v_1)}v_1\left(1- \frac{v_1}{v(t)}\right)\left[\int_{0}^{\infty}k(a)y(a, t){\rm d}a-u v(t)\right]\\ & +k_{2}\left[\int_{0}^{\infty}c(a)y(a, t){\rm d}a-b\right]z(t)\\ = &\left(1- \frac{x_1}{x(t)}\right)\left[\Lambda-d x(t)- \frac{ \beta x(t)v(t)}{1+ \alpha v(t)}\right]\\ & +\int_{0}^{\infty}F_2(a)\left(1- \frac{y_1(a)}{y(a, t)}\right) \frac{ \partial y(a, t)}{ \partial t} {\rm d}a\\ & + \frac{ \beta x_1}{u(1+ \alpha v_1)}\left(1- \frac{v_1}{v(t)}\right)\left[\int_{0}^{\infty}k(a)y(a, t){\rm d}a-u v(t)\right]\\ & +k_{2}\left[\int_{0}^{\infty}c(a)y(a, t){\rm d}a-b\right]z(t).\\ \end{aligned} \end{equation} (6.10)

    On substituting \Lambda = d x_1+ \beta x_1v_1/(1+ \alpha v_1) and \frac{ \partial y(a, t)}{ \partial t} = -(\mu(a)+p(a)z(t))y(a, t)-\frac{ \partial y(a, t)}{ \partial a} into Eq (6.10), one obtains

    \begin{equation} \begin{aligned} \frac{{\rm d}}{{\rm d}t}V_2(t) = &\left(1- \frac{x_1}{x(t)}\right)\left[-d (x(t)-x_1)+ \frac{ \beta x_1v_1}{1+ \alpha v_1}\right]- \frac{ \beta x(t)v(t)}{1+ \alpha v(t)}+ \frac{ \beta x_1 v(t)}{1+ \alpha v(t)} \\ &-\int_{0}^{\infty}F_2(a)\left(1- \frac{y_1(a)}{y(a, t)}\right) \left[ \frac{ \partial y(a, t)}{ \partial a}+(\mu(a)+p(a)z(t))y(a, t)\right]{\rm d}a\\ &+ \frac{ \beta x_1}{u(1+ \alpha v_1)}\left[\int_{0}^{\infty}k(a)y(a, t){\rm d}a-u v(t)- \frac{v_1}{v(t)}\int_{0}^{\infty}k(a)y(a, t){\rm d}a+uv_1\right]\\ & +k_{2}\left[\int_{0}^{\infty}c(a)y(a, t){\rm d}a-b\right]z(t).\\ \end{aligned} \end{equation} (6.11)

    A direct calculation shows that

    \begin{equation} \begin{aligned} y_1(a) \frac{ \partial}{ \partial a}G\left( \frac{y(a, t)}{y_1(a)}\right) = \left(1- \frac{y_1(a)}{y(a, t)}\right)\left( \frac{ \partial y(a, t)}{ \partial a}+\mu(a)y(a, t)\right). \end{aligned} \end{equation} (6.12)

    On substituting Eq (6.12) into Eq (6.11), we have

    \begin{equation} \begin{aligned} \frac{{\rm d}}{{\rm d}t}V_2(t) = &\left(1- \frac{x_1}{x(t)}\right)\left[-d (x(t)-x_1)+ \frac{ \beta x_1v_1}{1+ \alpha v_1}\right]- \frac{ \beta x(t)v(t)}{1+ \alpha v(t)}+ \frac{ \beta x_1 v(t)}{1+ \alpha v(t)} \\ &-\int_{0}^{\infty}F_2(a)y_1(a) \frac{ \partial}{ \partial a}G\left( \frac{y(a, t)}{y_1(a)}\right){\rm d}a -\int_{0}^{\infty}F_2(a)\left(1- \frac{y_1(a)}{y(a, t)}\right)p(a)y(a, t)z(t){\rm d}a\\ &+ \frac{ \beta x_1}{u(1+ \alpha v_1)}\left[\int_{0}^{\infty}k(a)y(a, t){\rm d}a-u v(t)- \frac{v_1}{v(t)}\int_{0}^{\infty}k(a)y(a, t){\rm d}a+uv_1\right]\\ & +k_{2}\left[\int_{0}^{\infty}c(a)y(a, t){\rm d}a-b\right]z(t).\\ \end{aligned} \end{equation} (6.13)

    Using integration by parts, it follows from Eq (6.13) that

    \begin{equation} \begin{aligned} \frac{{\rm d}}{{\rm d}t}V_2(t) = &\left(1- \frac{x_1}{x(t)}\right)\left[-d (x(t)-x_1)+ \frac{ \beta x_1v_1}{1+ \alpha v_1}\right]- \frac{ \beta x(t)v(t)}{1+ \alpha v(t)}+ \frac{ \beta x_1 v(t)}{1+ \alpha v(t)} \\ &-F_2(a)y_1(a)G\left( \frac{y(a, t)}{y_1(a)}\right){\Big |}_0^\infty+\int_{0}^{\infty}G\left( \frac{y(a, t)}{y_1(a)}\right) [F_2'(a)y_1(a)+F_2(a)y_1'(a)]{\rm d}a\\ &-\int_{0}^{\infty}F_2(a)\left(1- \frac{y_1(a)}{y(a, t)}\right)p(a)y(a, t)z(t){\rm d}a\\ &+ \frac{ \beta x_1}{u(1+ \alpha v_1)}\left[\int_{0}^{\infty}k(a)y(a, t){\rm d}a-u v(t)- \frac{v_1}{v(t)}\int_{0}^{\infty}k(a)y(a, t){\rm d}a+uv_1\right]\\ & +k_{2} z(t)\left[\int_{0}^{\infty}c(a)y(a, t){\rm d}a-b\right].\\ \end{aligned} \end{equation} (6.14)

    On substituting Eqs (6.7)–(6.8) into Eq (6.14), and noting that y_1'(a) = -\mu(a)y_1(a), y_1(0) = \beta x_1v_1/(1+ \alpha v_1) and y(0, t) = \beta x(t)v(t)/(1+ \alpha v(t)) , we obtain from Eq (6.14) that

    \begin{equation} \begin{aligned} \frac{{\rm d}}{{\rm d}t}V_2(t) = &-d \frac{(x(t)-x_1)^2}{x(t)}- \frac{ \beta x_1v_1}{1+ \alpha v_1}\left( \frac{x_1}{x(t)}-1\right)+ \frac{ \beta x_1 v(t)}{1+ \alpha v(t)} \\ &- \frac{ \beta x_1v_1}{1+ \alpha v_1}- \frac{ \beta x_1v_1}{1+ \alpha v_1}\ln \frac{x(t)v(t)(1+ \alpha v_1)}{x_1v_1(1+ \alpha v(t))}\\ &- \frac{ \beta x_1}{u(1+ \alpha v_1)}\int_{0}^{\infty}k(a)y_1(a)G\left( \frac{y(a, t)}{y_1(a)}\right){\rm d}a\\ &+ \frac{ \beta x_1}{u(1+ \alpha v_1)}\left[\int_{0}^{\infty}k(a)y(a, t){\rm d}a-u v(t)- \frac{v_1}{v(t)}\int_{0}^{\infty}k(a)y(a, t){\rm d}a+uv_1\right]\\ &-\int_{0}^{\infty}F_2(a)\left(1- \frac{y_1(a)}{y(a, t)}\right)p(a)y(a, t)z(t){\rm d}a+k_{2} z(t)\left[\int_{0}^{\infty}c(a)y(a, t){\rm d}a-b\right].\\ \end{aligned} \end{equation} (6.15)

    Noting that \frac{ \beta x_1}{u(1+ \alpha v_1)}\int_{0}^{\infty}k(a)y_1(a){\rm d}a = \frac{ \beta x_1}{u(1+ \alpha v_1)}uv_1 = \frac{ \beta x_1v_1}{1+ \alpha v_1} , we have from Eq (6.15) that

    \begin{equation} \begin{aligned} \frac{{\rm d}}{{\rm d}t}V_2(t) = &-d \frac{(x(t)-x_1)^2}{x(t)}- \frac{ \alpha \beta x_1(v(t)-v_1)^2}{(1+ \alpha v(t))(1+ \alpha v_1)^2}\\ &- \frac{ \beta x_1v_1}{1+ \alpha v_1}G\left( \frac{x_1}{x(t)}\right)- \frac{ \beta x_1v_1}{1+ \alpha v_1}G\left( \frac{1+ \alpha v(t)}{1+ \alpha v_1}\right) \\ &- \frac{ \beta x_1}{u(1+ \alpha v_1)}\int_{0}^{\infty}k(a)y_1(a)G\left( \frac{v_1y(a, t)}{v(t)y_1(a)}\right){\rm d}a\\ &+k_{2}\left( \frac{du\int_{0}^{\infty}c(a)\phi_1(a){\rm d}a}{( \alpha d+ \beta)\int_0^\infty k(a)\phi_1(a){\rm d}a}+b\right)(\mathscr{R}_1-1)z(t).\\ \end{aligned} \end{equation} (6.16)

    Since the function G(x) = x-1-\ln x\geq 0 for all x > 0 and G(x) = 0 holds iff x = 1 . Hence, V_2^{ \prime}(t)\leq 0 holds if \mathscr{R}_1 < 1 . It is readily seen from (6.16) that V_2^{ \prime}(t) = 0 if and only if

    \begin{equation} \begin{aligned} x(t) = x_1, \ \frac{y(a, t)v_1}{y_1(a)v(t)} = 1, \ \frac{1+ \alpha v(t)}{1+ \alpha v_1} = 1, \end{aligned} \end{equation} (6.17)

    for all a\geq 0 . It is easy to verify that the largest invariant subset of \{V_2^{ \prime}(t) = 0\} is the singleton E_1 . By Theorem 4.2, we see that if \mathscr{R}_1 < 1 < \mathscr{R}_0 , E_1 is locally asymptotically stable. Therefore, using LaSalle's invariance principle, we see that if \mathscr{R}_1 < 1 < \mathscr{R}_0 and (H4) hold, the global asymptotic stability of E_1 follows. This completes the proof.

    In the following, we define a positive function

    \begin{equation} \begin{aligned} F_3(a) = \frac{ \beta x^*}{u(1+ \alpha v^*)}\int_{a}^{\infty}k(u)e^{-\int_{a}^{u}(\mu(s)+p(s)z^*){\rm d}s}{\rm d}u. \end{aligned} \end{equation} (6.18)

    It is easy to show that

    \begin{equation} \begin{aligned} F_3(0) = \frac{ \beta x^*}{u(1+ \alpha v^*)}\int_{0}^{\infty}k(a)e^{-\int_{0}^{a}(\mu(s)+p(s)z^*){\rm d}s}{\rm d}a = 1, \end{aligned} \end{equation} (6.19)

    and

    \begin{equation} \begin{aligned} \lim\limits_{a \rightarrow\infty}F_3(a) = 0, \quad F_3'(a) = - \frac{ \beta x^*}{u(1+ \alpha v^*)}k(a)+(\mu(a)+p(a)z^*)F_3(a). \end{aligned} \end{equation} (6.20)

    Theorem 6.3. Assume there exists a positive constant k_{3} satisfying F_3(a)p(a) = k_{3}c(a) . If (H4) holds, then the CTL-activated infection steady state E^*(x^*, y^*(a), v^*, z^*) of system (1.3) is globally attractive if \mathscr{R}_1 > 1 .

    Proof. Let (x(t), y(a, t), v(t), z(t)) be any positive solution of system (1.3) with the boundary condition (1.4).

    Define

    \begin{equation} \begin{aligned} V_3(t) = &x^*G\left( \frac{x(t)}{x^*}\right)+\int_{0}^{\infty}F_3(a)y^*(a)G\left( \frac{y(a, t)}{y^*(a)}\right){\rm d}a\\ & + \frac{ \beta x^*}{u(1+ \alpha v^*)}v^*G\left( \frac{v(t)}{v^*}\right)+k_{3} z^*G\left( \frac{z(t)}{z^*}\right). \end{aligned} \end{equation} (6.21)

    Using a similar argument as that in the proof of Lemmas 7.1 and 7.2 in [27], one can show that all integrals involved in V_3(t) are finite.

    Calculating the derivative of V_3(t) along positive solutions of system (1.3), it follows that

    \begin{equation} \begin{aligned} \frac{{\rm d}}{{\rm d}t}V_3(t) = &\left(1- \frac{x^*}{x(t)}\right)\left[\Lambda-d x(t)- \frac{ \beta x(t)v(t)}{1+ \alpha v(t)}\right]\\ & +\int_{0}^{\infty}F_3(a)\left(1- \frac{y^*(a)}{y(a, t)}\right) \frac{ \partial y(a, t)}{ \partial t} {\rm d}a\\ & + \frac{ \beta x^*}{u(1+ \alpha v^*)}\left(1- \frac{v^*}{v(t)}\right)\left[\int_{0}^{\infty}k(a)y(a, t){\rm d}a-u v(t)\right]\\ & +k_{3}\left(1- \frac{z^*}{z(t)}\right)\left[\int_{0}^{\infty}c(a)y(a, t){\rm d}a-b\right]z(t).\\ \end{aligned} \end{equation} (6.22)

    On substituting \Lambda = d x^*+ \beta x^*v^*/(1+ \alpha v^*) and \frac{ \partial y(a, t)}{ \partial t} = -(\mu(a)+p(a)z(t))y(a, t)-\frac{ \partial y(a, t)}{ \partial a} into Eq (6.22), one obtains

    \begin{equation} \begin{aligned} \frac{{\rm d}}{{\rm d}t}V_3(t) = &\left(1- \frac{x^*}{x(t)}\right)\left[-d (x(t)-x^*)+ \frac{ \beta x^*v^*}{1+ \alpha v^*}\right]- \frac{ \beta x(t)v(t)}{1+ \alpha v(t)}+ \frac{ \beta x^* v(t)}{1+ \alpha v(t)} \\ &-\int_{0}^{\infty}F_3(a)\left(1- \frac{y^*(a)}{y(a, t)}\right) \left[ \frac{ \partial y(a, t)}{ \partial a}+(\mu(a)+p(a)z(t))y(a, t)\right]{\rm d}a\\ &+ \frac{ \beta x^*}{u(1+ \alpha v^*)}\left[\int_{0}^{\infty}k(a)y(a, t){\rm d}a-u v(t)- \frac{v^*}{v(t)}\int_{0}^{\infty}k(a)y(a, t){\rm d}a+uv^*\right]\\ & +k_{3}\left[z(t)\int_{0}^{\infty}c(a)y(a, t){\rm d}a-bz(t)-z^*\int_{0}^{\infty}c(a)y(a, t){\rm d}a+bz^*\right].\\ \end{aligned} \end{equation} (6.23)

    A direct calculation shows that

    \begin{equation} \begin{aligned} y^*(a) \frac{ \partial}{ \partial a}G\left( \frac{y(a, t)}{y^*(a)}\right) = \left(1- \frac{y^*(a)}{y(a, t)}\right)\left( \frac{ \partial y(a, t)}{ \partial a}+(\mu(a)+p(a)z^*)y(a, t)\right). \end{aligned} \end{equation} (6.24)

    On substituting Eq (6.24) into Eq (6.23), we get

    \begin{equation} \begin{aligned} \frac{{\rm d}}{{\rm d}t}V_3(t) = &\left(1- \frac{x^*}{x(t)}\right)\left[-d (x(t)-x^*)+ \frac{ \beta x^*v^*}{1+ \alpha v^*}\right]- \frac{ \beta x(t)v(t)}{1+ \alpha v(t)}+ \frac{ \beta x^* v(t)}{1+ \alpha v(t)} \\ &-\int_{0}^{\infty}F_3(a)y^*(a) \frac{ \partial}{ \partial a}G\left( \frac{y(a, t)}{y^*(a)}\right){\rm d}a\\ & -\int_{0}^{\infty}F_3(a)\left(1- \frac{y^*(a)}{y(a, t)}\right)p(a)y(a, t)(z(t)-z^*){\rm d}a\\ &+ \frac{ \beta x^*}{u(1+ \alpha v^*)}\left[\int_{0}^{\infty}k(a)y(a, t){\rm d}a-u v(t)- \frac{v^*}{v(t)}\int_{0}^{\infty}k(a)y(a, t){\rm d}a+uv^*\right]\\ & +k_{3}\left[z(t)\int_{0}^{\infty}c(a)y(a, t){\rm d}a-bz(t)-z^*\int_{0}^{\infty}c(a)y(a, t){\rm d}a+bz^*\right].\\ \end{aligned} \end{equation} (6.25)

    Using integration by parts, it follows from Eq (6.25) that

    \begin{equation} \begin{aligned} \frac{{\rm d}}{{\rm d}t}V_3(t) = &- \frac{d}{x(t)}(x(t)-x^*)^2- \frac{ \beta x^*v^*}{1+ \alpha v^*}\left( \frac{x^*}{x(t)}-1-\ln \frac{x^*}{x(t)}\right)\\ &- \frac{ \beta x^*v^*}{1+ \alpha v^*}\ln \frac{x^*}{x(t)}- \frac{ \beta x(t)v(t)}{1+ \alpha v(t)}+ \frac{ \beta x^* v(t)}{1+ \alpha v(t)} \\ &-F_3(a)y^*(a)G\left( \frac{y(a, t)}{y^*(a)}\right){\Big |}_0^\infty+\int_{0}^{\infty}G\left( \frac{y(a, t)}{y^*(a)}\right) [F_3'(a)y^*(a)+F_3(a)y^{*'}(a)]{\rm d}a\\ &-\int_{0}^{\infty}F_3(a)\left(1- \frac{y^*(a)}{y(a, t)}\right)p(a)y(a, t)(z(t)-z^*){\rm d}a\\ &+ \frac{ \beta x^*}{u(1+ \alpha v^*)}\left[\int_{0}^{\infty}k(a)y(a, t){\rm d}a-u v(t)- \frac{v^*}{v(t)}\int_{0}^{\infty}k(a)y(a, t){\rm d}a+uv^*\right]\\ & +k_{3}\left[z(t)\int_{0}^{\infty}c(a)y(a, t){\rm d}a-bz(t)-z^*\int_{0}^{\infty}c(a)y(a, t){\rm d}a+bz^*\right].\\ \end{aligned} \end{equation} (6.26)

    On substituting Eqs (6.19)–(6.20) into Eq (6.26), and noting that

    y^{*'}(a) = -(\mu(a)+p(a)z^*)y^*(a), y^*(0) = \beta x^*v^*/(1+ \alpha v^*)

    and

    \frac{ \beta x^*}{u(1+ \alpha v^*)}\int_{0}^{\infty}k(a)y^*(a){\rm d}a = \frac{ \beta x^*}{u(1+ \alpha v^*)}uv^* = \frac{ \beta x^*v^*}{1+ \alpha v^*},

    we obtain from Eq (6.26) that

    \begin{equation} \begin{aligned} \frac{{\rm d}}{{\rm d}t}V_3(t) = &-d \frac{(x(t)-x^*)^2}{x(t)}- \frac{ \alpha \beta x^*(v(t)-v^*)^2}{(1+ \alpha v^*)^2(1+ \alpha v(t))}\\ &- \frac{ \beta x^*v^*}{1+ \alpha v^*}G\left( \frac{x^*}{x(t)}\right)- \frac{ \beta x^*v^*}{1+ \alpha v^*}G\left( \frac{1+ \alpha v(t)}{1+ \alpha v^*}\right)\\ &-k_{3}\int_{0}^{\infty}k(a)y^*(a)G\left( \frac{y(a, t)v^*}{y^*(a)v(t)}\right){\rm d}a.\\ \end{aligned} \end{equation} (6.27)

    Since the function G(x) = x-1-\ln x\geq 0 for all x > 0 and G(x) = 0 holds iff x = 1 . Hence, V_3^{ \prime}(t)\leq 0 holds if \mathscr{R}_1 > 1 . It is readily seen from (6.27) that V_3^{ \prime}(t) = 0 if and only if

    \begin{equation} \begin{aligned} x(t) = x^*, \ v(t) = v^*, \ \frac{y(a, t)v^*}{y^*(a)v(t)} = 1, \ \frac{1+ \alpha v(t)}{1+ \alpha v^*} = 1, \end{aligned} \end{equation} (6.28)

    for all a\geq 0 . We now look for the invariant subset \mathscr{M} within the set

    \mathscr{M} = \{(x, y, v):x(t) = x^*, y(a, t) = y^*(a), v(t) = v^*\}.

    Because x(t) = x^*, y(a, t) = y^*(a) and v(t) = v^* on \mathscr{M} and consequently, it follows from the second equation of system (1.3) that

    \frac{{\rm d}}{{\rm d} a}y^*(a) = -\mu(a)y^*(a)-p(a)y^*(a)z(t),

    which yields z(t) = z^*. It is easy to verify that the largest invariant subset of \{V_3^{ \prime}(t) = 0\} is the singleton E^* . Therefore, using LaSalle's invariance principle, we see that if \mathscr{R}_1 > 1 and (H4) hold, the global attractivity of E^* follows. This completes the proof.

    In this section, we give some numerical examples for system (1.3) to illustrate the theoretical results in Sections 3 and 4. Based on the works of [28,29,30,31,32,33], parameter values of system (1.3) are summarized in Table 2. In the following, we will use the finite difference method [34] for all numerical simulations. Further, to ensure the precision of numerical simulations, time- and age-steps are both set as 0.05 .

    Table 2.  Parameter values for the age-structured HIV-1 model (1.3).
    Parameter Symbol Case 1 Case2 Case 3 Source
    Recruitment rate of healthy T cells \Lambda ( {\rm ml}^{-1}{\rm day}^{-1} ) 0.8\times10^6 0.98\times10^6 1.8\times10^6 Assumed
    Death rate of uninfected cells d ( {\rm day}^{-1} ) 0.01 0.01 0.01 [29]
    Infection rate \beta ( {\rm ml}\; {\rm day}^{-1} ) 1.3\times10^{-8} 1.3\times10^{-8} 1.3\times10^{-8} [28]
    Saturation constant \alpha 0.00015 0.00015 0.00015 [33]
    Death rate of infected cells \mu_m ({\rm day}^{-1}) 0.7 0.7 0.7 [30]
    Clearance rate of virions u ({\rm day}^{-1}) 23 23 23 [31]
    Death rate of CTL cells b ({\rm day}^{-1}) 0.5 0.5 0.5 [32]
    Killing rate of infected cells p_m ({\rm day}^{-1}) 0.00094 0.00094 0.00094 [32]
    Viral production rate of infected cells k_m ({\rm day}^{-1}) 11.349 11.349 11.349 [32]
    Proliferate rate of virus-specific CTL cells c_m ({\rm day}^{-1}) 0.003 0.003 0.003 Assumed

     | Show Table
    DownLoad: CSV

    As argued by Markowitz et al. [30], the faster rate of loss of virus-producing cells shows that the generation time for HIV-1 in vivo is correspondingly shorter, \sim2.0 days, which is obtained by summing up some factors, such as the eclipse time of \sim1.0 day . This value indicates that HIV-1 typically undergoes 180 generations per year in an infected person. Thus, the death rate of infected cells \mu_m in Table 2 is set as 0.7 {\rm day}^{-1} .

    When the viruses invade through cytomembrane, infected cells cannot die immediately, due to that it takes some time for viruses to replicate, transcribe and translate. For this reason, we assume that the death rate of infected cells increases from 0 to a peak value \mu_m with the infection age. The age-dependent per capita death rate is set as

    \begin{equation} \mu(a) = \left\{ \begin{aligned} &\mu_m\sin(0.1{\pi}a), & a \lt {a_0}, \\ &\mu_m, & a\geq{a_0}, \end{aligned} \right. \end{equation} (7.1)

    where {a_0} denotes the mean value of the time for viruses to replicate, transcribe and translate (in this section, a_0 is set as 5 day). Further, the maturing rate of new T cells and the kill ratio by T cells are selected as follows:

    \begin{equation} c(a) = \left\{ \begin{aligned} &c_m\sin(0.1{\pi}a), & a \lt {a_0}, \\ &c_m, & a\geq{a_0}, \end{aligned} \right.\quad p(a) = \left\{ \begin{aligned} &p_m\sin(0.1{\pi}a), & a \lt {a_0}, \\ &p_m, & a\geq{a_0}, \end{aligned} \right. \end{equation} (7.2)

    where c_m and p_m are the peak levels of c(a) and p(a) , respectively. As for the viral production rate of infected cells, it keeps at 0 for a short time a_1 , and then increases from 0 to a peak value k_m . Based on the works of [9,11], the specific function is set as follows

    \begin{equation} k(a) = \left\{ \begin{aligned} &0, & a \lt {a_1}, \\ &k_m(1-e^{-\theta(a-{a_1})}), & a\geq{a_1}, \end{aligned} \right. \end{equation} (7.3)

    where \theta determines how quickly k(a) reaches the saturation level k_m . For simplicity, we assume that \theta = 1 and {a_1} = 0.5 day in the following numerical simulations.

    We first choose parameter values as in Case 1 of Table 2. Then we have the basic reproduction number \mathscr{R}_0 = 0.8227 < 1 . By Theorem 4.1, we see that the infection-free steady state E_0(80003167.69, 0, 0, 0) is locally asymptotically stable. Numerical simulation illustrates this fact (see Figure 1).

    Figure 1.  The temporal solution found by numerical integration of system (1.3) with the boundary condition (1.4) and the initial condition x(0) = 1.5\times10^8 , y(0, 0) = 100 , v(0) = 200 , z(0) = 200 , where {\mathscr{R}_0} = 0.9131 < 1 .

    Next, we choose parameter values as in Case 2 of Table 2. By direct calculation, we get the basic reproduction number \mathscr{R}_0 = 1.0079 > 1 and the immune response reproduction number \mathscr{R}_1 = 0.9939 < 1 . By Theorem 4.1, we see that in addition to the infection-free steady state E_0(80003167.69, 0, 0, 0) , system (1.3) has a CTL-inactivated infection steady state E_1(97994001.72, 59.69\phi_1(a), 47.19, 0) which is locally asymptotically stable. Numerical simulation illustrates this fact (see Figure 2).

    Figure 2.  The temporal solutions found by numerical integration of system (1.3) with the boundary condition (1.4) and the initial condition x(0) = 1.5\times10^8 , y(0, 0) = 100 , v(0) = 200 , z(0) = 100 , where {\mathscr{R}_1} = 0.9939 < 1 < {\mathscr{R}_0} = 1.0079 .

    Remark 7.1. For system (1.3), a direct calculation shows that the characteristic equation of system (1.3) at the CTL-activated infection steady state E^* is of the form

    \begin{equation} \begin{aligned} \frac{ \beta x^*}{(1+ \alpha v^*)^2} \frac{\int_{0}^{\infty}k(a)\phi_1(a)\phi_2(a, z^*)e^{- \lambda a}{\rm d}a}{ \lambda+u} = 1+ \frac{ \beta v^*}{1+ \alpha v^*} \frac{1}{ \lambda+d} + \frac{ \beta x^*}{(1+ \alpha v^*)^2} \frac{1}{ \lambda+u}f( \lambda), \end{aligned} \end{equation} (7.4)

    where

    f( \lambda)\! = \! \frac{z^*\!\int_{0}^{\infty}\!\!\int_0^{a}k(a)p(s)y^*(s)\phi_1(a-s)\phi_2(a-s, z^*)e^{- \lambda(a-s)}{\rm d}s{\rm d}a\! \int_{0}^{\infty}c(a)\phi_1(a)\phi_2(a, z^*)e^{- \lambda a}{\rm d}a}{ \lambda+z^*\int_{0}^{\infty}\int_0^{a}c(a)p(s)y^*(s) \phi_1(a-s)\phi_2(a-s, z^*)e^{- \lambda(a-s)}{\rm d}s{\rm d}a}.

    We failed in studying the local asymptotic stability of E^* due to the complexity of Eq (7.4). In particular, we choose parameter values as in Case 3 of Table 2. By calculation, we have the immune-activated reproduction rate \mathscr{R}_1 = 1.8256 > 1 . As can be seen from the discussion in Section 3, in addition to the infection-free steady state E_0 and the CTL-inactivated infection steady state E_1 , system (1.3) has a unique CTL-activated infection steady state E^*(179981502.93,216.65\phi_1(a) \phi_2(a, 638.84), 93.90,638.84) . Numerical simulation indicates that if \mathscr{R}_1 > 1 , the CTL-activated infection steady state E^* is locally asymptotically stable in some special cases (see Figure 3).

    Figure 3.  The temporal solutions found by numerical integration of system (1.3) with the boundary condition (1.4) and the initial condition x(0) = 2.5\times10^8 , y(0, 0) = 100 , v(0) = 200 , z(0) = 800 , where {\mathscr{R}_1} = 1.8256 > 1 .

    In order to investigate the effects of CTL immune response, we carry out the following numerical simulations. For convenience, parameter values are chosen as in Table 2. From Figure 4, it is clear that the concentrations of infected cells and free virions with CTL immune response is obviously lower than those without CTL immune response, which indicates that CTL immune response indeed has an important impact on infected cells and free virions and can help our body to eliminate the virions.

    Figure 4.  The temporal solutions of infected cells and free virions with and without CTL immune response found by numerical integration of system (1.3) with the boundary condition (1.4) and the similar initial condition to Figure 3.

    From Figure 5, we further observe that when the proliferate rate of virus-specific CTL cells c_m increase from 0.002 to 0.004 ({\rm day}^{-1}) , both infected cells and free virions decreases to lower levels. This implies that CTL response can effectively reduce the quantity of infected cells and the serum viral load.

    Figure 5.  The temporal solutions of infected cells and free virions with different values of c_m found by numerical integration of system (1.3) with the boundary condition (1.4) and the similar initial condition to Figure 3.

    Remark 7.2. In our model, the death rate and the viral production rate of infected cells, the killing rate of infected cells by CTL and the proliferate rate of virus-specific CTL cells are assumed to vary according to the time a cell has been infected. Compared with the standard CTL response models without age structure, age-structure has more realistic representations of the biology of HIV-1 infection.

    We now carry out the sensitivity analysis of \mathscr{R}_1 . Through analysis of the sample derived from Latin hypercube sampling, we can obtain large efficient data in respect to different parameters of \mathscr{R}_1 . The first three figures in Figure 6 shows the scatter plots of \mathscr{R}_1 in respect to k_m , c_m and b , respectively, which implies that k_m and c_m are both positive correlative variables with \mathscr{R}_1 ; b is negative correlative variable with \mathscr{R}_1 . It is worth mentioning that k_m contributes more to \mathscr{R}_1 compared to c_m , namely, k_m is a more important factor in \mathscr{R}_1 . The last figure in Figure 6 shows a tornado plot of partial rank correlation coefficients with respect to \mathscr{R}_1 , indicating the importance of each parameter's uncertainty in contributing to \mathscr{R}_1 in the time to eradicate infection, which has the similar results to the first three figures in Figure 6.

    Figure 6.  Scatter plots of \mathscr{R}_1 with respect to \beta , \eta , \phi , \sigma , \xi and \gamma (first three figures). Tornado plot of partial rank correlation coefficients in respect to \mathscr{R}_1 (last figure).

    In the following, we carry out corresponding numerical simulations about the relation between the immune-activated reproduction rate \mathscr{R}_1 and the proliferate rate of virus-specific CTL cells c_m . As shown in Figure 7, we find that as the proliferate rate c_m decreases, the value of \mathscr{R}_1 changes from greater than one to less than one.

    Figure 7.  The curve of \mathscr{R}_1 with respect to the proliferate rate of virus-specific CTL cells c_m .

    In this work, we have investigated an age-structured HIV-1 infection model with CTL immune response. The model allows the production rate of viral particles, the death rate of productively infected cells, the removed rate of infected cells and the proliferate rate of virus-specific CTLs to vary and depend on the infection age. By constructing suitable Lyapunov functionals and using LaSalle's invariance principle, we have investigated the global dynamics of each of feasible steady state of system (1.3). By Theorem 6.1, we see that if the immune-inactivated reproduction rate {\mathscr{R}_0} is less than unity, the infection-free steady state is globally asymptotically stable. In this case, the virus is finally cleared up. By Theorem 6.2, we know that if the immune-activated reproduction rate {\mathscr{R}_1} satisfies {\mathscr{R}_1} < 1 < {\mathscr{R}_0} , sufficient conditions are derived for the global stability of the CTL-inactivated infection steady state. In this case, the infection becomes chronic but without CTL immune response. If {\mathscr{R}_1} > 1 , by Theorem 6.3, sufficient conditions are obtained for the global attractivity of the CTL-activated infection steady state. In this case, the infection turns to chronic with CTL immune response. We would like to point out here that Theorems 6.2 and 6.3 have room for improvement, we leave this for future work.

    This work was supported by the National Natural Science Foundation of China (Nos. 11871316, 11801340, 11371368), the Natural Science Foundation of Shanxi Province (Nos. 201801D121006, 201801D221007).

    The authors declare that they have no competing interests.



    [1] H. D. Kwon, Optimal treatment strategies derived from a HIV model with drug-resistant mutants, Appl. Math. Comput., 188 (2007), 1193–1204.
    [2] S. Bonhoeffer, R. M. May, G. M. Shaw, et al., Virus dynamics and drug therapy, Proc. Natl. Acad. Sci. USA, 94 (1997), 6971–6976.
    [3] D. D. Ho, A. U. Neumann, A. S. Perelson, et al., Rapid turnover of plasma virions and CD4+ lymphocytes in HIV-1 infection, Nature, 373 (1995), 123–126.
    [4] M. A. Nowak, R. M. Anderson, M. C. Boerlijst, et al., HIV-1 evolution and disease progression, Science, 274 (1996), 1008–1011.
    [5] M. A. Nowak, S. Bonhoeffer, G. M. Shaw, et al., Anti-viral drug treatment: Dynamics of resistance in free virus and infected cell populations, J. Theor. Biol., 184 (1997), 203–217.
    [6] A. S. Perelson and P. W. Nelson, Mathematical analysis of HIV-1 dynamics in vivo, SIAM Rev., 41 (1999), 3–44.
    [7] A. S. Perelson, D. E. Kirschner and R. De Boer, Dynamics of HIV infection of CD4+T cells, Math. Biosci., 114 (1993), 81–125.
    [8] A. S. Perelson, A. U. Neumann, M. Markowitz, et al., HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time, Science, 271 (1996), 1582–1586.
    [9] P. W. Nelson, M. A. Gilchrist, D. Coombs, et al., An age-structured model of HIV infection that allows for variations in the production rate of viral particles and the death rate of productively infected cells, Math. Biosci. Eng., 1 (2004), 267–288.
    [10] G. Huang, X. Liu and Y. Takeuchi, Lyapunov functions and global stability for age-structured HIV infection model, SIAM J. Appl. Math., 72 (2012), 25–38.
    [11] L. Rong, Z. Feng and A. S. Perelson, Mathematical analysis of age-structured HIV-1 dynamics with combination antiretroviral therapy, SIAM J. Appl. Math., 67 (2007), 731–756.
    [12] R. Xu, X. Tian and S. Zhang, An age-structured within-host HIV-1 infection model with virus-to-cell and cell-to-cell transmissions, J. Biol. Dyn., 12 (2017), 89–117.
    [13] G. W. Suryawanshi and A. Hoffmann, A multi-scale mathematical modeling framework to investigate anti-viral therapeutic opportunities in targeting HIV-1 accessory proteins, J. Theor. Biol., 386 (2015), 89–104.
    [14] J. Xu, Y. Geng and Y. Zhou, Global dynamics for an age-structured HIV virus infection model with cellular infection and antiretroviral therapy, Appl. Math. Comput., 305 (2017), 62–83.
    [15] J. Wang, J. Lang and X. Zou, Analysis of an age structured HIV infection model with virus-to-cell infection and cell-to-cell transmission, Nonlinear Anal. RWA, 34 (2017), 75–96.
    [16] J. Wang, R. Zhang and T. Kuniya, Global dynamics for a class of age-infection HIV models with nonlinear infection rate, J. Math. Anal. Appl., 432 (2015), 289–313.
    [17] A. Alshorman, C. Samarasinghe, W. Lu, et al., An HIV model with age-structured latently infected cells, J. Biol. Dyn., 11 (2017), 192–215.
    [18] Z. Liu and Z. Li, Molecular imaging in tracking tumor-specific cytotoxic T lymphocytes (CTLs), Theranostics, 4 (2014), 990–1001.
    [19] P. K. Roy and A. N. Chatterjee, T-cell proliferation in a mathematical model of CTL activity through HIV-1 infection, Proc. World Congr. Eng., 1 (2010), 1–6.
    [20] J. Cao, J. McNevin, S. Holte, et al., Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8 + T cells in primary HIV-1 infection, J. Virol., 77 (2003), 6867–6878.
    [21] C. Browne, Immune response in virus model structured by cell infection-age, Math. Biosci. Eng., 13 (2016), 887–909.
    [22] J. Pang, J. Chen, Z. Liu, et al., Local and global stabilities of a viral dynamics model with infection-age and immune response, J. Dyn. Differ. Equ., 31 (2019), 793–813.
    [23] R. R. Regoes, D. Ebert and S. Bonhoeffer, Dose-dependent infection rates of parasites produce the Allee effect in epidemiology, Proc. R. Soc. London B, 269 (2002), 271–279.
    [24] M. Iannelli, Mathematical Theory of Age-Structured Population Dynamics, Applied Mathematics Monographs, 7, Consiglio Nazionale delle Ricerche (C.N.R), Giardini Pisa, 1995, comitato nazionale per le scienze matematiche.
    [25] G. Webb, Theory of Nonlinear Age-Dependent Population Dynamics, Marcel Dekker, New York, 1985.
    [26] H. L. Smith and H. R. Thieme, Dynamical Systems and Population Persistence, American Mathematical Society, Providence, 2011.
    [27] J. Yang, R. Xu and X. Luo, Dynamical analysis of an age-structured multi-group SIVS epidemic model, Math. Biosci. Eng., 16 (2019), 636–666.
    [28] D. Burg, L. Rong, A. U. Neumann, et al., Mathematical modeling of viral kinetics under immune control during primary HIV-1infection, J. Theor. Biol., 259 (2009), 751–759.
    [29] N. M. Dixit and A. S. Perelson, Complex patterns of viral load decay under antiretroviral therapy: Influence of pharmacokinetics and intracellular delay, J. Theor. Biol., 226 (2004), 95–109.
    [30] M. Markowitz, M. Louie, A. Hurley, et al., A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and t-cell decay in vivo, J. Virol., 77 (2003), 5037–5038.
    [31] B. Ramratnam, S. Bonhoeffer, J. Binley, et al., Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis, Lancet, 354 (1999), 1782–1785.
    [32] J. Wang, M. Guo, X Liu, et al., Threshold dynamics of HIV-1 virus model with cell-to-cell transmission, cell-mediated immune responses and distributed delay, Appl. Math. Comput., 291 (2016), 149–161.
    [33] X. Zhou and J. Cui, Global stability of the viral dynamics with Crowley-Martin functional response, Bull. Korean Math. Soc., 48 (2011), 555–574.
    [34] M. Iannelli and F. Milner, The Basic Approach to Age-Structured Population Dynamics: Models, Methods and Numerics, Springer, 2017.
    [35] J. K. Hale and P. Waltman, Persistence in infinite-dimensional systems, SIAM J. Math. Anal., 20 (1989), 388–395.
    [36] P. Magal, Compact attractors for time periodic age-structured population models, Electron. J. Differ. Equ., 65 (2001), 1–35.
    [37] P. Magal, C. C. McCluskey and G. F. Webb, Lyapunov functional and global asymptotic stability for an infection-age model, Appl. Anal., 89 (2010), 1109–1140.
    [38] R. Xu, X. Tian and F. Zhang, Global dynamics of a tuberculosis transmission model with age of infection and incomplete treatment, Adv. Differ. Equ., 242 (2017), 1–34.
  • This article has been cited by:

    1. Qian Lin, Bin Deng, Jia Rui, Song-Bai Guo, Qingqing Hu, Qiuping Chen, Chi Tang, Lina Zhou, Zeyu Zhao, Shengnan Lin, Yuanzhao Zhu, Meng Yang, Yao Wang, Jingwen Xu, Xingchun Liu, Tianlong Yang, Peihua Li, Zhuoyang Li, Li Luo, Weikang Liu, Chan Liu, Jiefeng Huang, Min Yao, Mengni Nong, Liping Nong, Jinglan Wu, Na Luo, Shihai Chen, Roger Frutos, Shixiong Yang, Qun Li, Jing-An Cui, Tianmu Chen, Epidemiological Characteristics and Transmissibility of Human Immunodeficiency Virus in Nanning City, China, 2001–2020, 2021, 9, 2296-2565, 10.3389/fpubh.2021.689575
    2. Shuxing Cao, Zhijie Chen, Zhanwen Yang, Numerical representations of global epidemic threshold for nonlinear infection-age SIR models, 2023, 204, 03784754, 115, 10.1016/j.matcom.2022.07.021
    3. Jinhu Xu, Dynamic analysis of a cytokine-enhanced viral infection model with infection age, 2023, 20, 1551-0018, 8666, 10.3934/mbe.2023380
    4. Huizi Yang, Zhanwen Yang, Shengqiang Liu, Numerical threshold of linearly implicit Euler method for nonlinear infection-age SIR models, 2023, 28, 1531-3492, 70, 10.3934/dcdsb.2022067
    5. Shilpa Samaddar, Kalyan Manna, Malay Banerjee, 2024, Chapter 3, 978-981-97-7849-2, 29, 10.1007/978-981-97-7850-8_3
    6. Yafei Zhao, Hui Wu, Jie Lou, Global stability analysis of a nested multiscale model for intracellular and intercellular dynamics, 2025, 2025, 2731-4235, 10.1186/s13662-025-03942-8
  • Reader Comments
  • © 2019 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(4385) PDF downloads(478) Cited by(6)

Figures and Tables

Figures(7)  /  Tables(2)

Other Articles By Authors

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog